- 询价
- Cell Signaling Technology
- 5936
- USA
- 2025年12月05日
- W, IP
- Rabbit
- H,M,R
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 抗体英文名：
Phospho-PRAS40 (Ser183) Antibody
- 抗原：
synthetic peptide corresponding to residues surrounding Ser183 of human PRAS40 protein
- 应用范围：
W, IP
- 宿主：
Rabbit
- 库存：
大量
- 适应物种：
H,M,R
- 保质期：
详见说明书
- 级别：
详见MSDS文件
- 供应商：
CST
- 是否单克隆：
2
- 保存条件：
-20°c
- 规格：
100 ul (10 western blots)/carrier free & custom formulation / quantity
| 规格： | 产品价格： | ￥请询价 | |
|---|---|---|---|
| 规格： | 100 ul (10 western blots) | 产品价格： | ￥请询价 |
| 规格： | carrier free & custom formulation / quantity | 产品价格： | ￥请询价 |
pathway more info application references datasheet PDF MSDS PDF protocols
Applications Key: W=Western Blotting IP=Immunoprecipitation
Reactivity Key: H=Human M=Mouse R=Rat
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.
| Applications | Reactivity | Sensitivity | MW (kDa) | Source |
|---|---|---|---|---|
| W IP | H M (R) | Endogenous | 40 | Rabbit |
| Protocols |
|
|---|---|
| Specificity / Sensitivity | Phospho-PRAS40 (Ser183) Antibody recognizes endogenous levels of PRAS40 protein only when phosphorylated at Ser183. |
| Source / Purification | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ser183 of human PRAS40 protein. Antibodies are purified by protein A and peptide affinity chromatography. Western Blotting
Western blot analysis of extracts from HeLa cells, untreated or treated with LY294002 #9901 (with and without serum starvation) or with Rapamycin #9904, using Phospho-PRAS40 (Ser183) Antibody (upper) or PRAS40 (D23C7) XP® Rabbit mAb #2691 (lower). Western Blotting
Western blot analysis of extracts from HeLa cells treated with hIGF-I #8917, in the absence (-) or presence (+) of λ phosphatase, using Phospho-PRAS40 (Ser183) Antibody (upper) or PRAS40 (D23C7) XP® Rabbit mAb #2691 (lower). |
| Background | Many growth factors and hormones induce the phosphoinositide 3-kinase signaling pathway, which results in the activation of downstream effector proteins such as the serine/threonine kinase Akt (1,2). One known Akt substrate is a 40 kDa, proline-rich protein (PRAS40) that binds to 14-3-3 proteins (2). PRAS40 also binds mTOR to transduce Akt signals to the mTOR complex. Inhibition of mTOR signaling stimulates PRAS40 binding to mTOR, which in turn inhibits mTOR activity (3). PRAS40 interacts with raptor in mTOR complex 1 (mTORC1) in insulin-deprived cells and inhibits the activation of the mTORC1 pathway mediated by the cell cycle protein Rheb. Phosphorylation of PRAS40 by Akt at Thr246 relieves PRAS40 inhibition of mTORC1 (4). mTORC1 in turn phosphorylates PRAS40 at Ser183 (5). |
| Application References | Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know ! |
| Companion Products |
For Research Use Only. Not For Use In Diagnostic Procedures. |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Using Phospho‐Motif Antibodies to Determine Kinase Substrates
comprising both the phosphorylated residue and the surrounding residues that determine kinase specificity, with degenerate residues taking up the remaining positions. Currently, several categories of phospho?motif antibody are commercially available
Optimized Protocol to Make Phospho-Specific Antibodies that Work
, not simply its level of expression. In this review, we will discuss both the design of the phosphopeptide immunogen and immunization. The affinity purification of the phospho-specific antibody as well as the methods most suitable for characterizing
Absorption Control in Immunohistochemistry Using Phospho-Peptides Immobilized on Magnetic Beads
neutralization of phospho-specific antibodies with phospho-peptides immobilized on magnetic beads. This technique allows for sequestration of antibody–peptide complex from the incubation solution, minimizing the risk of formation of unblocked antibodies capable
技术资料暂无技术资料 索取技术资料
